Navigation Links
DATATRAK Awarded First Study With Kreara Solutions
Date:3/8/2011

CLEVELAND, March 8, 2011 /PRNewswire/-- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it has been awarded its first study by Kreara Solutions, a Contract Research Organization (CRO) in India, with which the Company had partnered in 2010. Both companies will work together in order to execute a Phase II study for the Dermatology Division of a Global Enterprise, whose core competencies include the fields of Health Care, Nutrition and High-Tech Materials.  

The trial will be conducted in Japan and employ several CROs based in Japan, India and the USA to conduct project management, monitoring, data management and other study-specific services. All of the CROs, as well as the Sponsor, will be utilizing DATATRAK eClinical™ for Electronic Data Capture (EDC) and Medical Coding.

Anoop P. Ambika, Kreara's CEO and Managing Director said, "Kreara has always strived to provide quality and timely data management services to its clients in adherence to the internal standards and standards set by the client and regulatory bodies. Kreara looks forward to working closely with DATATRAK to deliver the challenging requirements of this trial, all the while adhering to the cost, quality and timeliness as envisioned during the planning phase."

"DATATRAK's unified eClinical platform is an ideal solution for studies which intend to employ multiple CROs from various geographic locations around the world," said Laurence P. Birch, DATATRAK's Chairman and CEO.  "We can help companies to streamline their study communications, provide a single point of access for all study users, and enable both the Sponsor and CROs to gain real-time access to patient data. We are excited to embark on this first study with Kreara, especially as we guide them through the design and deployment of their study as an Enterprise Transfer client."

Abou
'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
2. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
3. DATATRAK International Reports First Quarter Results for 2008
4. European Division of Global Top 20 Pharmaceutical Company Awards Phase III Trial to DATATRAK
5. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
6. DATATRAK eClinical(TM) Supports Multifaceted Studies
7. DATATRAK to Present at 2009 SCDM Annual Conference
8. DATATRAK Signs 6 Year Study with New Device Client
9. DATATRAK Attends 13th Annual DIA Workshop in Japan for Clinical Data Management
10. DATATRAK International, Inc. Announces Year-End Backlog
11. DATATRAK Signs Five-Year Registry Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 Research and Markets  has ... Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, ... http://photos.prnewswire.com/prnh/20130307/600769 ... category in IVD testing with competitive participation by ... employers, criminal justice personnel, and sports use drug ...
(Date:8/1/2014)... 1, 2014  VanDeMark Chemical Inc., ... of phosgene and phosgene derivatives in ... has acquired Framochem Kft, a leading European-based manufacturer ... . The purchase unites two ... of the world,s largest, independent manufacturers of products ...
(Date:8/1/2014)... , Aug. 1, 2014 RoundTable ... focused exclusively on the healthcare industry, announced today ... The Lubrizol Corporation ("Lubrizol"). Lubrizol, a Berkshire Hathaway ... and supplies technologies to customers in the global ... transaction were not disclosed. Vesta is ...
Breaking Medicine Technology:Drugs of Abuse Testing Markets (Lab-Based, Professional POC, Home, Employment, Criminal Justice Markets) 2VanDeMark Chemical Inc. Acquires Framochem 2VanDeMark Chemical Inc. Acquires Framochem 3VanDeMark Chemical Inc. Acquires Framochem 4RoundTable Healthcare Partners Announces Sale of Vesta Funding, Inc. to The Lubrizol Corporation 2
(Date:8/1/2014)... research at Washington University School of Medicine in St. ... in males and frequently are more harmful than similar ... malignant brain tumors, are diagnosed twice as often in ... do not survive as long. , The researchers found ... cancer risk, is significantly less active in male brain ...
(Date:8/1/2014)... -- The U.S. Food and Drug Administration announced on ... help fight type 2 diabetes. Jardiance (empagliflozin) ... regimens to control blood sugar levels in the overall ... Office of Drug Evaluation II in the FDA,s Center ... statement. The FDA also recommended that Jardiance be ...
(Date:8/1/2014)... 2014 The evolving healthcare landscape ... pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor ... and resources to enhance patient care and profitability. ... critical issues to give independent pharmacists the tools ... , ThoughtSpot show attendance experienced a nearly 70% ...
(Date:8/1/2014)... Growing prevalence of chronic ailments, ... are boosting healthcare market growth, although a reduction ... increasing generic consumption is a major challenge. , ... 2013, having grown at a Compound Annual Growth ... of the Health Transformation Program (Saglikta Donus, um ...
(Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Patients with ... pulmonary disease (COPD) have a new weapon to battle ... Thursday. The agency approved a new treatment, ... the third leading killer of Americans. COPD, which is ... as chronic bronchitis and emphysema. Patients with ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
... Urges Senate to Quickly Pass this Important Lifesaving ... Connor, American Lung Association President and CEO:Today in ... in favor with a strong bipartisan majority for ... the Family Smoking Prevention and Tobacco Control Act ...
... Finding could steer caregivers away from situations that would add ... levels of a stress hormone may be responsible for the ... children with a certain type of autism. , ... not experience the normal twofold increase of cortisol upon waking ...
... CITY, Mo., April 2 Argus Health Systems, Inc., ... received an award from the Flaspohler Research Group as ... of Interest" in the 2008 PBM Survey of ... ranked by survey participants based on specific attributes, including ...
... know where and when patients and staff interact, giving ... influenza transmission patternsATLANTA, April 2 Radianse, Inc. today ... University Hospital Midtown, Atlanta, is using the Radianse ... know early and reliably where, when and with whom ...
... 2009 Can we always see what is in front of ... and Cognitive Neuroscience at The City College of New York (CCNY), ... Journal of Neuroscience " by Professor Ro and colleagues from the ... brainwave activity is in a trough. , "We may have our ...
... (omega-3s), namely EPA and DHA found in seafood and ... benefits, but evidence of other benefits continues to stack ... menopausal women and healthier weight loss in obese dieters ... these topics are summarized in the March 2009 ...
Cached Medicine News:Health News:U.S. House of Representatives Again Votes with a Strong Bipartisan Majority in Favor of Granting the U.S. FDA Regulatory Control Over Tobacco Products 2Health News:Asperger Syndrome Tied to Low Cortisol Levels 2Health News:Argus Honored by Flaspohler Research Group as Highest-Rated PBM for 'No Conflicts of Interest' 2Health News:Radianse Announces Real-Time Tracking of Emory ED Staff and Patients to Trace and Contain Infectious Disease Spread 2Health News:Neuroscientists demonstrate link between brainwave acticity and visual perception 2Health News:Omega-3s May Benefit Newborns, Menopausal Women and Obese Individuals 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0454....
Medicine Products: